CC
SPRY icon

Casdin Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Casdin Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,600,000
Closed -$18.6M – 46
2025
Q4 		$18.6M Hold
1,600,000
– – 1.16% 16
2025
Q3 		$16.1M Buy
+1,600,000
New +$23M 1.34% 15

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Casdin Capital's SPRY Position: Q1 2026 in Review

Casdin Capital sold out of ARS Pharmaceuticals (SPRY) in Q1 2026, closing a stake of 1,600,000 shares — an estimated $18.6M sold.

Casdin Capital first reported a position in SPRY in Q3 2025 and held it in 2 quarters. The position peaked at $18.6M in Q4 2025. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Casdin Capital reported no remaining ARS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Casdin Capital sold 1,600,000 ARS Pharmaceuticals shares in Q1 2026, an estimated $18.6M.
  • Casdin Capital first reported a position in ARS Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Casdin Capital's ARS Pharmaceuticals position peaked at $18.6M in Q4 2025.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.